Weight-loss drugs could reduce the risk of cancer developing in obese people
A retrospective macro-study revealed that the use of GLP-1 agonists is associated with a reduction in the overall risk of cancer among obese or overweight patients
‘Obesity can kill’: Controversial campaign by Ozempic drugmaker sparks backlash
Novo Nordisk’s campaign, which aims to speak ‘without filters’ by declaring obesity a disease, has been strongly criticized on social media: ‘It’s indecent’
The Ozempic universe expands: These drugs also treat fatty liver disease
A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction
What’s the best way to lose weight, following a diet or taking drugs like Ozempic?
María José Castro Alija|
Now we have medications for obesity, but they are not for losing a couple of kilos. An integrative approach of all available measures is needed
When Ozempic fails: Study sheds light on why some patients lose half as much weight as others
Researchers have used artificial intelligence to find out why some people have a better response to GLP-1 agonists
Aging researcher Coleen Murphy: ‘All the doctors in the longevity field are taking metformin’
The Princeton researcher has published a book in which she reviews what is known about the science of living longer and healthier lives
Oprah Winfrey returns to TV with controversial special on obesity: ‘Making fun of my weight was national sport’
The businesswoman presented a special on diets and drugs such as Ozempic, which she previously criticized and now, prudently, embraces: ‘Let’s stop shaming other people for being overweight or how they choose to lose or not lose weight’
Ozempic, or how the weight loss company has injected $560 billion into Novo Nordisk and Eli Lilly since 2023
Citi estimates that the fight against obesity will generate revenue of $158 billion in 2035. The main risk for the sector is the difficulty in guaranteeing supply